deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT04875533

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 60 YEARS OF AGE AND OLDER IN JAPAN, KOREA, AND TAIWAN

Sponsor: Pfizer

Conditions Pneumococcal Disease
Interventions 13vPnC 20vPnC PPSV23 Saline
Updated 19 times since 2021 Last updated: Oct 15, 2024 Started: Jun 14, 2021 Primary completion: May 13, 2022 Completion: May 13, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04875533, this PHASE3 trial focuses on Pneumococcal Disease and remains completed. Sponsored by Pfizer, it has been updated 19 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Dec 2023 · 11 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

19 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Dec 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Dec 2024 [monthly]

    Completed PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

▶ Show 14 earlier versions

  1. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE3

  2. Jan 2023 — Dec 2023 [monthly]

    Completed PHASE3

  3. Sep 2022 — Jan 2023 [monthly]

    Completed PHASE3

  4. Jul 2022 — Sep 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  6. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  7. Apr 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  8. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  9. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE3

  10. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  11. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  12. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  13. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  14. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ansan-si, South Korea , Chuo-ku, Japan , Daegu, South Korea , Fukuoka, Japan , Hachioji-shi, Japan , Incheon, South Korea , Itoshima, Japan , Naka-ku, Yokohama-Shi, Japan , New Taipei City, Taiwan , Osaka, Japan and 9 more locations